Multiple Myeloma

The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.

Latest News

These studies highlight that multiple myeloma outcomes are not solely determined by disease biology or available therapies. | Image Credit: wladimir1804 - stock.adobe.com
Highlighting Disparities in Myeloma Outcomes, the Impacts of Comorbidities

June 28th 2025

Disparities in multiple myeloma outcomes and the need for equitable care were the focus of 2 posters presented at the 2025 American Society of Clinical Oncology annual meeting.

Westin Forrestal Princeton | Image: Westin
Value-Based Care Calls for Putting Novel Therapies Closer to Patients

June 19th 2025

Mansi Shah, MD
Stem Cell Transplant Remains Cost-Effective Option for MM: Mansi Shah, MD

June 11th 2025

The investigators said real-world use of allo-SCT appeared to be receding as a preferred option after relapse, even before these new data. | Image credit: ibreakstock - stock.adobe.com
Auto-SCT Superior to Allo-SCT in Relapsed Myeloma After First-Line Auto-SCT

June 7th 2025

IVBM Phoenix logo | Image: AJMC
Translating Best Practices and Ensuring Equitable Care as the Treatment Landscape Evolves

May 19th 2025

Experts Weigh in on Multiple Myeloma

Explore the expanding role of bispecific antibody therapies and strategies for managing cytokine release syndrome and infection risks. Dive into real-world data on teclistamab and talquetamab, and uncover new approaches to optimize patient outcomes.

AJMC Insights logo displayed on a blue abstract background with light and dark wave patterns.
Continuing Medical Education
View All
June 29th 2025

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Hematology, Hematologic Cancer, Oncology
June 29th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
June 29th 2025

Closing Gaps in CLL Care: Managed Care Insights and Strategies

1.5 Credit / Hematologic Cancer, Oncology
June 29th 2025

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

1.0 Credit / Oncology, Hematology, Hematologic Cancer
June 29th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
June 29th 2025

Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens

1.5 Credits / Hematologic Cancer, Hematology, Oncology

More News

bottle of pills
June 15th 2022

Vitamin D Provides Therapeutic Benefit Among Patients With MM, Review Says

Skylar Jeremias
A literature review revealed that supplementation with vitamin D could provide therapeutic benefits for patients with multiple myeloma (MM) who are undergoing chemotherapy. However, more research is needed to confirm findings.
Preferred IMiDs Regimens Based on Line of Therapy
June 14th 2022

Preferred IMiDs Regimens Based on Line of Therapy

Two experts highlight their preferred treatment options for RRMM based on each line of therapy the patient will need.
What Factors Into IMiDs Treatment Selection for Patients With RRMM?
June 14th 2022

What Factors Into IMiDs Treatment Selection for Patients With RRMM?

Drs Kaufman and Richter outline important considerations physicians should be aware of when selecting IMiD therapy for a patient with RRMM.
IMiDs and Triplet Regimens in MM and RRMM Therapy
June 7th 2022

IMiDs and Triplet Regimens in MM and RRMM Therapy

Dr Jonathan L. Kaufman discusses the role immunomodulatory drugs (IMiDs) play within triplet regimens for patients with RRMM.
RRMM: An Overview
June 7th 2022

RRMM: An Overview

Joshua Richter, MD, and Jonathan L. Kaufman, MD, define and provide a basic understanding of relapsed/refractory multiple myeloma (RRMM).
High Economic Burden of MM, Particularly Within 1 Year of Diagnosis, Says French Study
June 4th 2022

High Economic Burden of MM, Particularly Within 1 Year of Diagnosis, Says French Study

Jaime Rosenberg
As more treatments continue to enter the market for multiple myeloma (MM), the cost of associated treatments is expected to continue climbing, with the researchers of the study emphasizing the need for more effective and options to help mitigate costs.
Low Socioeconomic Status May Account for Ethnic Survival Disparities in MM
June 3rd 2022

Low Socioeconomic Status May Account for Ethnic Survival Disparities in MM

Jaime Rosenberg
The researchers found that socioeconomic status likely drives survival disparities between Hispanic patients and non-Hispanic whites (NHWs). They also found that, while both underserved populations, Hispanics and non-Hispanic blacks have different survival outcomes compared with NHWs.
cancer patient in hospital bed
May 28th 2022

Is There a Possibility of a Cure in Multiple Myeloma?

Jaime Rosenberg
Multiple myeloma has historically been considered a chronic disease, even as newer treatments have greatly improved rates of survival for the disease.
Myelofibrosis May Predict Extramedullary Disease in MM
May 27th 2022

Myelofibrosis May Predict Extramedullary Disease in MM

Jaime Rosenberg
The researchers found that extramedullary disease at diagnosis was significantly more common in patients with bone marrow fibrosis.
Highlighted image of the spine
May 21st 2022

Radiomics-Based Models Can Accurately Diagnose MM and Bone Metastases, Study Finds

Rose McNulty
Differentiation between multiple myeloma (MM) and bone metastases from other cancers can be difficult, but radiomics-based models have potential to improve diagnostic accuracy.
Multiple Myeloma spelled out on a screen
May 18th 2022

Serum IgG Subclass May Be Indicator of Treatment Effect in Multiple Myeloma

Jaime Rosenberg
The researchers found that among subclasses, IgG1 expression was most prominent in samples from patients with multiple myeloma, and expression of IgG1 changed significantly before, throughout, and following treatment.
man in hospital bed
May 15th 2022

Repurposing a Drug Used for Alcohol Abuse May Overcome MM Treatment Resistance

Jaime Rosenberg
According to recent findings, metabolizing disulfiram into diethyldithiocarbamate-copper complex creates a proteasome inhibitor-like treatment that enables the efficient killing of treatment-resistant multiple myeloma (MM) cells.
multiple myeloma image
May 12th 2022

PET/CT Can Assess Early Treatment Response in Newly Diagnosed MM

Laura Joszt, MA
Negative positron emission tomography/CT examinations 6 months after induction therapy in patients with newly diagnosed multiple myeloma (MM) is associated with prolonged time to next treatment and overall survival.
cells
May 8th 2022

Energy Metabolism in Clonal Plasma Cells May Drive Survival Outcomes in Newly Diagnosed MM

Jaime Rosenberg
The findings, say the researchers, provide a basis for future exploration of the activity of energy metabolism pathways in clonal plasma cells of patients newly diagnosed with the disease.
health graphic
May 4th 2022

Levels of Certain Thyroid Hormone May Help With Risk Stratification in MM

Jaime Rosenberg
With survival of multiple myeloma ranging from less than 1 month to over 10 years, the researchers highlighted the importance of risk stratification to quickly identify patients who are high risk with poor prognosis and could benefit from different treatment strategies and close surveillance.
diversity graphic
May 3rd 2022

Researchers Show How RWD on Racial Outcomes in MM Can Complement Clinical Trial Data

Jaime Rosenberg
Of the 5800 patients included in study, 20% were Black, which the researchers say adequately represents disease incidence among the population.
Incorporating RWE Into Future Decision-Making
April 26th 2022

Incorporating RWE Into Future Decision-Making

Our panel concludes with their plans to incorporate RWE into MM management in the future.
MM Unmet Needs
April 26th 2022

MM Unmet Needs

Dr Baljević discusses unmet needs that are typically seen in the management of MM.
doctor with patient in hospital bed
April 26th 2022

Predicting Early Severe Infection in Patients With Newly Diagnosed MM

Laura Joszt, MA
A simple score can identify the patients at risk of severe infection within 4 months of initiating treatment, highlighting candidates to be treated with prophylactic antibiotics.
Kidneys
April 23rd 2022

Study Finds Autologous Stem Cell Transplantation Safe, Effective in Patients With Multiple Myeloma, Chronic Kidney Disease

Rose McNulty
Chronic kidney disease is a common complication in multiple myeloma, and a recent study found it is safe to treat this patient population with autologous stem cell transplantation.
Image of words multiple myeloma
April 22nd 2022

Mesenchymal Stem Cells Induce Cell Proliferation, Inhibit Dexamethasone Effectiveness in MM

Rose McNulty
Mesenchymal stem cells are known to promote tumor growth and metastasis in multiple myeloma (MM), but a recent study found they may also inhibit the effects of the corticosteroid dexamethasone, a common medication for the hematologic malignancy.
Educating on RWE
April 20th 2022

Educating on RWE

Dr Richter delves into how we can better educate patients and physicians on RWE to improve decision-making.
MM and Non-Comparative RWE
April 20th 2022

MM and Non-Comparative RWE

The panel moves the discussion to non-comparative RWE and how that can play a part in their decision-making for MM therapy.
heart image
April 14th 2022

Higher Risk of CV Mortality Seen in Patients With MM Compared With General Population

Rose McNulty
While studies have explored risks among patients with multiple myeloma, recent research is the first to compare cardiovascular mortality risk in multiple myeloma to that of the general population.
RWE Decision-Making Barriers
April 12th 2022

RWE Decision-Making Barriers

Dr Beveridge explains potential barriers a physician can encounter when implementing RWE into MM therapy.
Incorporating RWE in MM Decision-Making
April 12th 2022

Incorporating RWE in MM Decision-Making

The panel elaborate on how they’ve incorporated RWE into their decision-making processes for their patients with MM.
a magnifying glass over a report with a 3D graph on it
April 11th 2022

New Minimal Residual Disease Assessment Could Detect Disease Progression Earlier in MM

Skylar Jeremias
Flow–minimal residual disease (MRD) assessment in patients with multiple myeloma (MM) was found to be a good tool for early detection of MRD and could aid providers in treatment decision-making.
Image of health care costs
April 9th 2022

Study Finds Potential Association Between Allostatic Load, Worse Overall Survival in MM

Rose McNulty
A recent study aimed to identify associations between socioeconomic status, allostatic load, and clinical trial end points in patients with multiple myeloma (MM).
The Value of RWE in MM
April 5th 2022

The Value of RWE in MM

Jay Weaver, PharmD, MPH, and Muhamed Baljević, MD, FACP, discuss how RWE can affect the management of MM.
MM and Real-World Evidence
April 5th 2022

MM and Real-World Evidence

Dr Richter relays some of the differences between real-world evidence (RWE) and RCT data, as well as how they can work together when determining therapy.
<1
...
56789101112>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo